Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07085845 | The Self-Sampling Pilot Study(SOLOPilot) | completed | N/A | 50 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05993429 | Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma | completed | — | 200 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 26, 2026 |
| clinicaltrials |
| NCT07368530 | Using Machine Learning to Identify Responders to TACE or HAIC for uHCC | completed | — | 3,000 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04524702 | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | completed | Phase 2 | 10 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05166239 | HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | completed | Phase 2 | 66 | Peking UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363629 | Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled Trial | completed | N/A | 120 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05641896 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers(18F-FAPI-74 GI) | completed | Phase 2 | 109 | SOFIEINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05746195 | Optimization of Adaptive Text Messages for Cancer Survivors (OATS II) | completed | N/A | 46 | University of California, San FranciscoOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03377491 | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | completed | Phase 3 | 571 | NovoCure Ltd.INDUSTRY | 20 | Jan 21, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04550624 | Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma | completed | Phase 2 | 27 | Shanghai Jiahui International HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06426927 | PeLear CCC: Proyecto Latino Contra Cancer Colorrectal(PeLear CCC) | completed | N/A | 60 | University of North Carolina, Chapel HillOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07349576 | Precision Dietary Intervention Improves Postoperative Energy Intake, Nutritional Status, and Recovery in Patients Undergoing Hepatectomy for Liver Cancer: A Randomized Controlled Trial | completed | N/A | 139 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05349331 | Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma(WATCH) | completed | Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT07329920 | Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy | completed | — | 300 | Guo ShiWeiOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04459468 | Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC | completed | — | 17 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04567615 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | completed | Phase 2 | 266 | Bristol-Myers SquibbINDUSTRY | 17 | Jan 8, 2026 | clinicaltrials |
| NCT05876026 | MRI T1 Relaxation Time in Rectal Cancer | completed | — | 44 | Vejle HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06760234 | Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis | completed | — | 247 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07321613 | Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients | completed | — | 545 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03290937 | Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05348811 | HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | completed | Phase 2 | 25 | Zhongda HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03199274 | Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer | completed | Phase 2 | 104 | Thomas Jefferson UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05100082 | Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma | completed | — | 263 | TakedaINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07304388 | HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC | completed | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT01618643 | Aceto-whitening in the Assessment of Gastrointestinal Neoplasia | completed | — | 197 | Portsmouth Hospitals NHS TrustOTHER_GOV | 1 | Dec 24, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT03246516 | Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers(DELOGAST) | completed | N/A | 258 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03745794 | Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery | completed | Phase 2 | 136 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04400357 | Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors(PORTAL) | completed | N/A | 268 | Ruijin HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05024513 | Biliary Drainage Plus HAIC in Locally Advanced pCCA | completed | Phase 2 | 127 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | completed | Phase 2 | 23 | Emory UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05419362 | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | completed | Phase 2 | 42 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04862949 | Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC | completed | — | 131 | CHA UniversityOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04798781 | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | completed | Phase 2 | 16 | Andrew Hendifar, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03015038 | Study of the Immune Response in Colon Adenocarcinoma(IMCO) | completed | — | 100 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03071458 | Mutational Landscape in Hepatocellular Carcinoma(MUTHEC) | completed | — | 808 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05280379 | Trained Immunity in Thyroid Carcinoma and Colon Carcinoma | completed | — | 33 | Radboud University Medical CenterOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07272265 | The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study | completed | N/A | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT02921256 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | completed | Phase 2 | 363 | National Cancer Institute (NCI)NIH | 2 | Dec 4, 2025 | clinicaltrials |
| NCT03628248 | Effect of Endovascular Inferior Mesenteric Artery Embolization on Colonic Perfusion Prior to Rectal Surgery for Rectal Tumor or Sigmoid Colon Surgery(AMIREMBOL) | completed | N/A | 10 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread(CheckMate 9N9) | completed | Phase 1 / Phase 2 | 325 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2026source: clinicaltrials